Marina Udier, Nouscom CEO
October 19, 2026 02:00 AM EDT
Nouscom raises $135M in Series D for lead cancer vaccine
Clinical-stage cancer biotech Nouscom has raised $135 million in an oversubscribed Series D funding round to take its lead vaccine through to a Phase 2 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source